Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026
M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026
Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026
Clinical Data Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial–again pharminent September 3, 2026
Regulatory Johnson & Johnson’s multiple myeloma treatment secures EC approval pharminent August 24, 2026
Clinical Data Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future pharminent August 20, 2026
Pipeline Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts pharminent August 5, 2026
M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026
M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
Regulatory GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug pharminent July 23, 2026
Regulatory Celcuity gains FDA approval for closely watched breast cancer drug pharminent July 15, 2026
M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B pharminent July 14, 2026
Clinical Data GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China pharminent July 10, 2026
Regulatory Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe pharminent June 29, 2026
Regulatory Replimune gets early August decision date for twice-rejected melanoma drug pharminent June 26, 2026
Clinical Data Pfizer drug acquired in Seagen deal disappoints in lung cancer study pharminent June 23, 2026
Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs pharminent June 22, 2026